P2.13-03 Real-Life Experience With Brigatinib in Pretreated EML4-ALK Translocated NSCLC Patients

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1398
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P2.13-06 TP53 Status in Relation to Response to Anti-Alk Agents in Patients With EML4-ALK-Translocated NSCLC

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Brigatinib Bei ALK-positivem NSCLC

Im Focus Onkologie
2017English

P2.13-05 Real-World Clinical Benefit of Continuing Crizotinib Beyond Progression Disease (CBPD) in Patients With Advanced ALK-Positive NSCLC.

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

PL02.03 Brigatinib vs Crizotinib in Patients With ALK Inhibitor-Naive Advanced ALK+ NSCLC: First Report of a Phase 3 Trial (ALTA-1L)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

HER2 Regulates Cancer Stem-Like Cell Phenotype in ALK Translocated NSCLC

International Journal of Oncology
Cancer ResearchOncology
2017English

P1.15-03 Clinical Characteristics of Long-Term Survivors With Nivolumab in Pretreated Advanced NSCLC From Real-World Data (RWD)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Pcn216 - Contemporary Real-World Evidences on Alk+ NSCLC Patients in Italy

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P2.13-01 Brigatinib Use in England – Where Next?

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

1330: Brigatinib Efficacy and Safety in Patients (Pts) With Anaplastic Lymphoma Kinase (ALK)-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) in a Phase 1/2 Trial

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy